Literature DB >> 7541188

Inhibition of constitutive and inducible nitric oxide synthase: potential selective inhibition.

J M Fukuto1, G Chaudhuri.   

Abstract

Nitric oxide (NO) is a molecule that has been shown to be involved in a diverse array of physiological events. A variety of disease states and disorders are, in fact, due to either an over- or an underproduction of NO. As a result of the ubiquity and diversity of NO-mediated phenomenon, pharmacological manipulation is difficult. NO biosynthesis is the result of an oxidation of a terminal nitrogen on the amino acid arginine by a class of enzymes generally referred to as the nitric oxide synthases (NOSs). Since the various isoforms of NOS are distributed in cells and tissues according to their function, there is the possibility that manipulation of NO levels can be accomplished by designing specific pharmacological agents targeted at a single NOS isoform. Thus, this review discusses general inhibition of the NOSs by a variety of agents and then focuses on the possibility of developing agents for specific isoform inhibition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541188     DOI: 10.1146/annurev.pa.35.040195.001121

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  15 in total

1.  Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism.

Authors:  Toshio Hayashi; Teiji Esaki; Daigo Sumi; Tapan Mukherjee; Akihisa Iguchi; Gautam Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

2.  Differential effects of nitric oxide synthase inhibitors on endothelium-dependent and nitrergic nerve-mediated vasodilatation in the bovine ciliary artery.

Authors:  J Overend; W Martin
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

3.  Protective effects of cyclosporin-A in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; M Ferlito; B Deodato; M Arlotta; L Minutoli; G M Campo; A Bova; C Quartarone; G Urna; A Sardella; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 4.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Effects of nitric oxide modulating activities on development of enteric nervous system mediated gut motility in chick embryo model.

Authors:  Hossein-Ali Arab; Samad Muhammadnejad; Seyed-Muhammad Faghihi; Hossein Hassanpour; Ahad Muhammadnejad
Journal:  J Biosci       Date:  2014-12       Impact factor: 1.826

6.  Pontine nitric oxide modulates acetylcholine release, rapid eye movement sleep generation, and respiratory rate.

Authors:  T O Leonard; R Lydic
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

7.  Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine.

Authors:  E Galea; S Regunathan; V Eliopoulos; D L Feinstein; D J Reis
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

8.  Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine.

Authors:  S Pfeiffer; E Leopold; K Schmidt; F Brunner; B Mayer
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  The nitric oxide synthase inhibitor NG-Nitro-L-arginine increases basal forebrain acetylcholine release during sleep and wakefulness.

Authors:  Jacqueline Vazquez; Ralph Lydic; Helen A Baghdoyan
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

10.  Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.

Authors:  Genaro G Ortiz; Gloria A Benítez-King; Sergio A Rosales-Corral; Fermín P Pacheco-Moisés; Irma E Velázquez-Brizuela
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.